Travere Therapeutics, Inc. (TVTX) stock
TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$51.10+1.40 (+2.82%)
Close on Nov 17, 2026Market cap $4.82BP/E –Yield –
Travere Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Travere Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was $22.91M. For fiscal 2026 it was -$2.08M. The highest annual figure on record is -$2.08M in fiscal 2026.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Dec 31, 2025 | -$2.08M | – |
| FY2025 | Dec 31, 2024 | -$280.27M | – |
| FY2024 | Dec 31, 2023 | -$349.61M | – |
| FY2023 | Dec 31, 2022 | -$299.09M | – |
| FY2022 | Dec 31, 2021 | -$186.68M | – |
| FY2021 | Dec 31, 2020 | -$151.58M | – |
| FY2020 | Dec 31, 2019 | -$116.95M | – |
| FY2019 | Dec 31, 2018 | -$61.37M | – |
| FY2018 | Dec 31, 2017 | -$35.99M | – |
| FY2017 | Dec 31, 2016 | -$42.08M | – |
| FY2016 | Dec 31, 2015 | -$37.36M | – |
| FY2015 | Dec 31, 2014 | -$74.41M | – |
| FY2014 | Dec 31, 2013 | -$24.56M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027 | Jun 30, 2026 | $8.19M | +499.4% |
| Q1 FY2027 | Mar 31, 2026 | -$11.70M | – |
| Q4 FY2026 | Dec 31, 2025 | -$14.29M | – |
| Q3 FY2026 | Sep 30, 2025 | $40.72M | – |
| Q2 FY2026 | Jun 30, 2025 | $1.37M | – |
| Q1 FY2026 | Mar 31, 2025 | -$29.87M | – |
| Q4 FY2025 | Dec 31, 2024 | -$48.65M | – |
| Q3 FY2025 | Sep 30, 2024 | -$44.91M | – |
| Q2 FY2025 | Jun 30, 2024 | -$57.36M | – |
| Q1 FY2025 | Mar 31, 2024 | -$129.36M | – |
| Q4 FY2024 | Dec 31, 2023 | -$84.75M | – |
| Q3 FY2024 | Sep 30, 2023 | -$81.11M | – |
| Q2 FY2024 | Jun 30, 2023 | -$93.00M | – |
| Q1 FY2024 | Mar 31, 2023 | -$90.75M | – |
| Q4 FY2023 | Dec 31, 2022 | -$80.39M | – |
| Q3 FY2023 | Sep 30, 2022 | -$83.40M | – |
| Q2 FY2023 | Jun 30, 2022 | -$70.42M | – |
| Q1 FY2023 | Mar 31, 2022 | -$64.89M | – |
| Q4 FY2022 | Dec 31, 2021 | -$92.67M | – |
| Q3 FY2022 | Sep 30, 2021 | -$23.84M | – |
| Q2 FY2022 | Jun 30, 2021 | -$28.70M | – |
| Q1 FY2022 | Mar 31, 2021 | -$41.48M | – |
| Q4 FY2021 | Dec 31, 2020 | -$111.92M | – |
| Q3 FY2021 | Sep 30, 2020 | -$13.00M | – |
| Q2 FY2021 | Jun 30, 2020 | -$17.26M | – |
| Q1 FY2021 | Mar 31, 2020 | -$9.41M | – |
| Q4 FY2020 | Dec 31, 2019 | -$22.88M | – |
| Q3 FY2020 | Sep 30, 2019 | -$29.06M | – |
| Q2 FY2020 | Jun 30, 2019 | -$31.69M | – |
| Q1 FY2020 | Mar 31, 2019 | -$33.33M | – |
| Q4 FY2019 | Dec 31, 2018 | -$106.00K | – |
| Q3 FY2019 | Sep 30, 2018 | -$30.79M | – |
| Q2 FY2019 | Jun 30, 2018 | -$16.92M | – |
| Q1 FY2019 | Mar 31, 2018 | -$13.56M | – |
| Q4 FY2018 | Dec 31, 2017 | -$10.71M | – |
| Q3 FY2018 | Sep 30, 2017 | -$5.99M | – |
| Q2 FY2018 | Jun 30, 2017 | -$9.16M | – |
| Q1 FY2018 | Mar 31, 2017 | -$10.12M | – |
| Q4 FY2017 | Dec 31, 2016 | -$14.04M | – |
| Q3 FY2017 | Sep 30, 2016 | -$16.28M | – |
See a number that looks wrong?